文献速递母胎医学

在高风险队列中针对常染色体显性遗传病的单基因无创产前筛查

Single gene non-invasive prenatal screening for autosomal dominant conditions in a high-risk cohort.
PubMed 文献 · Prenat Diagn · 2023-04-16

该临床试点于2020年3月至2021年11月在高风险生殖遗传门诊开展,为253名孕妇提供覆盖30个基因的单基因无创产前筛查(NIPS-SGD),并行诊断性检测。228例完成检测中8例(3.5%)阳性,78人诊断性检测未发现假阳性或假阴性;41例(25.9%)分子诊断中34例(82.9%)超出NIPS-SGD范围。结论认为NIPS-SGD可导致更早产前诊断、增强监测和目标基因分析,但不应替代有临床指征的诊断性检测。

要点

  • NIPS-SGD在高风险人群中可早期发现致病变异并改变部分病例的临床管理。
  • 41例分子诊断中34例(82.9%)超出NIPS-SGD覆盖范围。
  • NIPS-SGD不应替代有临床指征的诊断性检测。

核心结论

  • 在高风险人群中,NIPS-SGD可导致更早的产前诊断、增强监测和目标基因分析,但不应替代有临床指征的诊断性检测。
  • 可能的偶然发现包括亲本诊断和错配亲子关系。

研究设计与样本

  • 2020年3月至2021年11月开展的NIPS-SGD临床试点。
  • NIPS-SGD panel评估30个基因的致病变异,提供给有以下指征的孕妇:男方年龄≥40岁、颈项透明层(NT)≥3.5 mm、胎儿异常或panel覆盖疾病的家族史。
  • 同时提供诊断性检测。

主要发现

  • NIPS-SGD共开具253人:88人(34.8%)因胎儿异常,96人(37.9%)因男方年龄≥40岁,37人(14.6%)因NT增高,5人(2.0%)因家族史。
  • 228人(90.1%)完成检测,其中8人(3.5%)阳性。
  • 78人诊断性检测未发现假阳性或假阴性结果。
  • 41人(25.9%)获得分子诊断,其中34人(82.9%)超出NIPS-SGD范围。
  • 阳性NIPS-SGD在5例中改变了医疗管理。

临床怎么用

  • 原文结论指出NIPS-SGD在高风险人群中可导致更早产前诊断、增强监测和目标基因分析,但不应替代有临床指征的诊断性检测。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSE: To determine the utility of single gene non-invasive prenatal screening (NIPS-SGD) in a high-risk reproductive genetics clinic. METHODS: A clinical pilot for NIPS-SGD was conducted from March 2020 to November 2021. A NIPS-SGD panel assessing pathogenic variants in 30 genes was offered to pregnant individuals for the following indications: (1) advanced sperm age ≥40 years, (2) nuchal translucency (NT) ≥ 3.5 mm, (3) fetal anomaly, or (4) family history of a condition covered by the panel. Diagnostic testing was offered concurrently. RESULTS: NIPS-SGD was ordered for 253 individuals: 88 (34.8%) for fetal anomalies, 96 (37.9%) for advanced sperm age, 37 (14.6%) for increased NT, and 5 (2.0%) for family history. Among 228 (90.1%) completed tests, 8 (3.5%) were positive. Diagnostic testing for 78 individuals revealed no false positive or negative results. Of 41 (25.9%) individuals who received a molecular diagnosis, 34 (82.9%) were outside the scope of NIPS-SGD. Positive NIPS-SGD altered medical management in five cases. CONCLUSIONS: NIPS-SGD in a high-risk population can lead to earlier prenatal diagnosis, enhanced surveillance, and targeted genetic analysis, but should not replace clinically indicated diagnostic testing. Potential incidental findings include parental diagnoses and misattributed parentage.

来源:Prenat Diagn,查看原文。版权归原作者所有。

引用

  1. Adams S, Llorin H, Maher O, et al. Single gene non-invasive prenatal screening for autosomal dominant conditions in a high-risk cohort. Prenat Diagn. 2023. PMID: 37021343. doi:10.1002/pd.6351

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。